CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' narrative. UnitedHealth Group is charging patients a markup for key life-saving drugs that could easily exceed their cost by a factor of ten or more,
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension drug.
Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.
We recently published a list of 10 Companies Reflect Market Decline. In this article, we are going to take a look at where UnitedHealth Group Incorporated (NYSE:UNH) stands against other companies that reflect market decline.
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.
But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it had made less than analysts expected.
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
Jan. 16 at 1:45 p.m. ETUnitedHealth Group's Optum Rx unit made a commitment to pass through 100% of rebates negotiated with drugmakers to the client. | UnitedHealth Group reported $5.5 billion in profit for the fourth quarter of 2024,
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
UnitedHealth, the biggest insurance company in America, is receiving backlash after an FTC report revealed that it was overcharging cancer patients by 1000%.
A bill filed Thursday (Jan. 16) in the Arkansas Legislature would prohibit pharmacy benefit managers and insurance companies from obtaining retail permits and operating pharmacies and mail order services